Home Companies Catalysts Deep Dives
Verquvo vericiguat APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaCVRM
Launch2021-01-19
US LOE2031-01-01
Peak Sales Est$1000M
Formulations[{"id":"verquvo-po","doses":"2.5mg, 5mg, 10mg","route":"PO","setting":"PATIENT_SELF","frequency":"QD
Companies
MRK (ORIGINATOR)100%
Mechanism: sGC stimulator
Expert: Soluble guanylate cyclase stimulator enhancing NO-cGMP pathway
Everyday: Improves blood vessel relaxation in heart failure
Targets: ["SGC"]
Revenue History
PeriodRevenue ($M)
2023$285M
2024$412M
Programs (1)
IndicationStageKey StudyRegional Status
Heart Failure (worsening)APPROVEDVICTORIA[{"stage":"APPROVED","region":"US","approval_date":"2021-01-19"}]
Notes
Partnered with Bayer. For worsening HF. Underperforming expectations.
Data from Supabase · Updated 2026-03-24